Dentsply Sirona upgraded to Buy from Neutral at BofA

BofA upgraded Dentsply Sirona (XRAY) to Buy from Neutral with a price target of $17, up from $13. Ahead of 2026 guidance due next week, which “could be a clearing event,” the firm thinks the risk/reward “finally skews positive,” the analyst tells investors. While earnings may cause volatility as management could cut the dividend, commit to elevated investments, and introduce below Street guidance, the firm would see this as a potential attractive opportunity as these decisions and progress in repairing distributor relationships could support growth stabilizing over the medium term, BofA added.